The test, which searches for fragments of DNA 200 basepairs or longer that are characteristic of diseased mucosa, may eventually compete with diagnostics like Exact Sciences' Cologuard.
A US expansion was logical because "there is high recognition [here] of the value that diagnostics can bring to the patient and to the oncologist," its CEO said.
The French firm reached five new deals covering 15 countries for its Immunoscore test, which helps physicians assess colon cancer prognosis.
Almac is developing the assay to enroll patients for clinical trials used to develop repotrectinib, an investigational tyrosine kinase inhibitor.
Biomatrica's sample collection tubes ensure quality preservation of circulating tumor DNA and cells, promoting high-quality liquid biopsy results, Exact said.
The measures are part of a long-term plan for the National Health Service that will be rolled out across the country to detect 3 out of every 4 cancers at an early stage.
The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.
Immunoscore Colon predicts the risk of recurrence in patients with early-stage colon cancer and guides oncologists in decisions about therapies for stage II and III colon cancers.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The researchers argued that fecal immunochemical test could be used as "rule-in" test for patients with ambiguous symptoms.